Continuing Education Activity

Coronary computed tomography angiography (CCTA) is a noninvasive imaging modality that uses multidetector computed tomography with intravenous contrast to visualize the coronary arteries, cardiac anatomy, and surrounding structures with high spatial resolution. This modality enables accurate assessment of coronary artery stenosis, plaque morphology (calcified, noncalcified, or mixed), and congenital or anomalous coronary anatomy. CCTA plays a central role in evaluating patients with stable chest pain, equivocal stress testing, or low-to-intermediate pretest probability of coronary artery disease, offering an excellent negative predictive value and facilitating early diagnosis, risk stratification, and preventive management.

Through participation in this course, clinicians strengthen their ability to appropriately select patients for CCTA, interpret key imaging findings, and integrate results into evidence-based clinical decision-making. Learners gain practical knowledge of technical considerations, image acquisition, radiation dose optimization, and common pitfalls, as well as an understanding of how CCTA compares with functional testing and invasive angiography. The course also emphasizes interdisciplinary collaboration among cardiologists, radiologists, technologists, and referring clinicians to optimize diagnostic accuracy, patient safety, and downstream care planning.

Objectives:

• Identify appropriate candidates for coronary computed tomography angiography based on clinical indications and pretest coronary artery disease probability.
• Differentiate between the indications and contraindications for coronary computed tomography angiography compared to other coronary artery disease evaluation modalities, such as stress testing or invasive coronary angiography.
• Assess coronary computed tomography angiography images effectively to identify and evaluate coronary artery stenosis, plaque characteristics, and other relevant findings.
• Collaborate with radiologists and cardiologists in interpreting coronary computed tomography angiography results and developing appropriate treatment plans.

Introduction

Chest pain is the most common symptom of coronary artery disease (CAD), posing a significant diagnostic challenge for clinicians. Despite remarkable strides in medical and procedural treatments, cardiovascular disease persists as a major global health concern. Addressing this burden demands timely and cost-effective diagnostic tools. Coronary computed tomography angiography (CCTA) is a crucial diagnostic modality for CAD assessment. This noninvasive approach is invaluable for patients with low-to-intermediate pretest probabilities of ischemic heart disease, underscoring its role in evaluating stable patients who do not require immediate revascularization.[1][2][3]

While invasive coronary angiography remains the diagnostic gold standard, CCTA is increasingly recognized as a noninvasive, low-risk alternative. This modality circumvents the hazards associated with invasive procedures and expedites assessments for patients at intermediate risk of CAD. Given the minute dimensions and dynamic nature of epicardial coronary arteries, CCTA requires precise spatial and temporal resolution. Spatial resolution determines the smallest distinguishable distance between 2 points, while temporal resolution dictates how rapidly images of moving structures can be captured. With the advent of 64-slice multi-detector CT systems and contemporary technologies, CCTA now boasts the necessary spatial and temporal resolution to visualize even the most distal coronary artery segments (see Image. Coronary Computed Tomography Angiography).

Anatomy and Physiology

The CCTA is a radiographic procedure that enables clinicians to closely evaluate the heart and its components, including the atria, ventricles, pericardium, great cardiac vessels, myocardium, and intracardiac valves. This diagnostic test involves a radiographic assessment of the epicardial coronary arteries, facilitated using a contrast agent. Although standard cardiac CT windows may provide limited visualization of adjacent pulmonary and osseous structures, CCTA provides valuable information. A thorough understanding of coronary anatomy is imperative for accurate interpretation of CT coronary angiograms.

Normal Coronary Anatomy

The left main artery arises from the posterior left aortic cusp. This artery typically measures 1 to 2 cm in length and bifurcates into the left anterior descending artery (LAD) and the left circumflex artery (LCx). In 0.41% of patients, the left main artery is absent, and both the LAD and LCx arise individually from the left aortic cusp. The LAD exits to the left of the pulmonary artery and travels down anteriorly in the anterior interventricular groove. Major branches from the LAD include septal perforators, which supply the anterior two-thirds of the interventricular septum, and diagonal branches, which supply the lateral wall of the left ventricle (LV).

The LCx turns back into the left atrioventricular groove and gives branches called the obtuse marginal, which supply the lateral aspect of the LV. The LCx, through its course, is covered by the left auricle. In one-third of cases, the left main artery trifurcates into the LAD, LCx, and ramus intermedius, which runs between the course of LAD and LCx, supplying the anterolateral wall of the LV. The right coronary artery (RCA) originates from the anterior aspect of the right aortic cusp. The RCA runs forward into the right atrioventricular (AV) groove until the crux (a point of intersection of the right AV groove and posterior interventricular groove) divides into the posterolateral branch and the posterior descending artery (PDA). In a left-dominant system, the PDA arises from the LCx. 

Indications

Studies assessing the diagnostic performance of CCTA have typically compared its ability to detect significant coronary lesions (stenoses greater than 50%) with lesions identified in the same patients on subsequent invasive coronary angiography. Initial studies of 64-slice multidetector CT reported diagnostic sensitivity of 94%, specificity of 97%, positive predictive value of 87%, and negative predictive value of 99%.[4] These initial studies typically excluded patients with atrial fibrillation, atrial premature contractions, ventricular premature contractions, prior history of CAD, and an inability to tolerate beta-blockade. The reported accuracy of CCTA in chronic atrial fibrillation is 95.2% for sensitivity and 97.6% for specificity.[5]

CCTA protocols typically include an initial noncontrast, low-radiation-dose phase. This noncontrast portion of the study can yield high-quality data on cardiac anatomical structures that may not be adequately visualized with other noninvasive imaging modalities, eg, transthoracic echocardiography or cardiac magnetic resonance imaging. Contrast images can be instrumental in diagnosing and managing adult congenital heart disease (CHD). Simple CHD includes an atrial septal defect, patent foramen ovale, ventricular septal defect, and bicuspid aortic valve.

Complex CHD can also be assessed with reasonable accuracy, including Ebstein anomaly, truncus arteriosus, hypoplastic left heart syndrome, transposition of great arteries, Tetralogy of Fallot, and tricuspid atresia. Specifically, with cases of complex CHD, many of these patients benefit from surgical repair and can survive to adulthood. CCTA provides an accurate, timely, and cost-effective means of initial diagnosis and follow-up care in these patients.

Calcium scoring (CAC score) is a valuable parameter derived from the noncontrast portion of a CCTA and is also known as the Agatston score. This score is used to stratify patients into low-, intermediate-, and high-risk groups for future CAD development. While CAC scores are useful in identifying asymptomatic individuals who require more intensive preventative treatment, they are rarely appropriate for symptomatic patients. Guidelines suggest that CCTA may be a more appropriate diagnostic tool for symptomatic patients with an intermediate pretest probability of coronary disease. CAC scores are determined by assigning a weighted density score to the location of calcium with the highest attenuation, measured in Hounsfield units during the initial noncontrast phase of a CCTA, and then multiplying it by the area of calcification.

CAC scores are classified into 4 risk assessment categories based on their values: 

• Very low risk: 0
• Mildly increased risk: 1–99
• Moderately increased risk: 100–299
• Moderate-to-severely increased risk: ≥ 300 [6] 

Patients with CAC scores of 0 or 1 to 10 have a very low lifetime risk of adverse cardiovascular events. However, results from studies have shown that patients with mild CAC scores of 1 to 10 are at 3 times the risk of developing CAD compared with those with a CAC score of 0. These findings have led to additional investigations into the roles of noncalcified coronary artery plaque, rapid atherosclerosis, and plaque destabilization in the development of coronary heart disease. Assessing these additional plaque features using CAC scoring alone can be challenging, particularly for noncalcified coronary artery plaques, which can range from nonobstructive to significantly stenotic.

CCTA can also be used to diagnose coronary anomalies. As with CAD, invasive coronary angiography has been the diagnostic gold standard. However, owing to the temporal and spatial resolution of modern CT scanners, CCTA has emerged as a viable and robust noninvasive alternative for assessing coronary anatomy. Coronary anomalies are present in less than 1% of the population, and presentations can range from benign, incidental findings to dramatic, as in the case of sudden cardiac death. Anomalous coronary arteries are classified into 3 general groups: anomalies of origin and course, intrinsic coronary anatomy anomalies, and anomalies of arterial termination.

In addition to assessing coronary anatomy, CCTA enables 3-dimensional imaging of the entire heart and the spatial arrangement of anomalous coronary arteries, which can, in turn, provide prognostic information. Newer CCTA applications in perfusion and fractional flow reserve areas are on the horizon and are set to expand the diagnostic utility of cardiac CT. Additionally, transcatheter structural invasive procedures are now routinely performed and are guided by noninvasive cardiac imaging, specifically CCTA preprocedurally.[7][8][9][10] According to the Society of Cardiovascular Computed Tomography 2021 Expert Consensus Document on Coronary Computed Tomographic Angiography, the following are the appropriate indications for CCTA in patients with CAD.[11]

CCTA in native vessels for evaluation of stable coronary artery disease: 

• CCTA is appropriate as a first-line investigation in patients with no known CAD, with typical stable, atypical, or angina-equivalent symptoms.
• CCTA is appropriate as a first-line investigation in patients with known CAD, with typical stable, atypical, or angina equivalent symptoms.
• CCTA is appropriate for evaluating CAD following inconclusive functional testing.
• CCTA may be appropriate for the assessment of asymptomatic individuals who are at high risk of having CAD.
• CCTA is rarely appropriate in asymptomatic low-to-intermediate risk patients or symptomatic very low-risk individuals.

CCTA for evaluation of stable coronary artery disease post-revascularization:

• CCTA is appropriate in symptomatic patients with coronary stent diameters greater than 3 mm.
• CCTA may be appropriate for symptomatic patients with coronary stent diameters of less than 3 mm, particularly those with thin struts of less than 100 micrometers in proximal, nonbifurcating vessels.
• CCTA is appropriate for evaluating graft patency in patients with prior coronary artery bypass grafting. 
• CCTA is appropriate for assessing grafts and other structures before redoing cardiac surgery.

CCTA for evaluation of stable coronary artery disease using fractional flow reserve or CT perfusion:

• CCTA may be appropriate for the functional assessment of intermediate stenosis (30%-90%) in multivessel disease to guide decisions regarding invasive coronary angiography and revascularization.
• Adding fractional flow reserve or stress CT enhances the overall diagnostic value of CCTA. 

CCTA for evaluation of stable CAD in miscellaneous conditions:

• Valvular heart disease and low risk for CAD
• Nonischemic cardiomyopathy and low risk for CAD
• Coronary artery anomalies
• Screening of coronary allograft vasculopathy
• Scar assessment in patients who cannot undergo cardiac MRI
• Electrocardiogram gating of patients undergoing CCTA for aortic dissection and pulmonary embolism to assess CAD in men older than 45 and women older than 55

Contraindications

There are generally no absolute contraindications to performing a CCTA. However, a history of a severe anaphylactic reaction to iodinated contrast precludes a repeat contrast administration. The following are the relative contraindications:

• Acute thyroid storm
• Pregnancy
• Renal insufficiency (defined as creatinine clearance less than 30 mL/min/1.73 m²) 
• Inability to hold breath for more than 5 seconds
• Patients on radioactive iodine therapy
• Hemodynamic instability
• Acute decompensated heart failure
• Patient's height and weight above the recommended scanner thresholds

Equipment

The Society for Cardiovascular Computed Tomography recommends that, at a minimum, a 64-slice CT scanner be used for CCTA.[11] Dual-head power-injection pumps should be used to enable biphasic and triphasic injection protocols. Digital images should be stored in the Digital Imaging and Communications in Medicine format. A picture archiving and communication system should be available to enable review of the entire image set acquired during the scan. 

Personnel

The Society for Cardiovascular Computed Tomography recommends that CCTAs be performed by technologists adequately trained to use contrast injection devices and to perform cardiac CTs and CCTAs. One team member should be proficient in inserting peripheral intravenous catheters. During image acquisition, a team member certified in advanced cardiac life support should also be available. Finally, a clinician trained in administering beta-blockers and nitroglycerin should also be present during the scan. The interpreting clinician should be trained in CCTA in accordance with the respective clinical competence statements of the American College of Cardiology and the American Heart Association. 

Preparation

Key facts to consider for the preparation of CCTA include the following:

• The decision to proceed with a CCTA should be made only if the results will affect a patient’s clinical management or prognosis and if there is a reasonable expectation of obtaining interpretable images.
• Any potential contraindications should be reviewed, and subsequent evaluations of the risks and benefits should be conducted.
• Informed consent should be obtained before the initiation of the CCTA.
• The patient should have no solid food for 4 hours before the exam. Liquid food may be continued. 
• The patient should refrain from caffeine for 12 hours before the test.
• Preferably, intravenous access should be obtained from the right antecubital vein using an 18-gauge catheter. This minimizes streak artifact during image acquisition and enables rapid contrast infusion at rates of 5 to 7 mL/s. Hand veins should be avoided, as this typically requires a 20-gauge or smaller catheter, which can result in slower flow rates. Central lines should not be used unless rated for power injection.
• The ideal heart rate for CCTA image acquisition is 60 beats per minute or less. An oral beta-blocker is typically administered 2 hours before the test; intravenous beta-blocker administration may be added at the time of the test. Oral metoprolol tartrate at 50 to 100 mg is typically used as a pre-medication. Alternatives include oral atenolol, intravenous esmolol, calcium channel blockers, and ivabradine.
• Nonsteroidal anti-inflammatory drugs should be held 24 to 48 hours before the study to reduce the risk of contrast nephropathy. Glucophage should be held for 48 hours after the procedure. Consider holding phosphodiesterase inhibitors if nitrates are anticipated. Nitrates vasodilate the coronary arteries, improving visualization of the coronary arteries and stenoses when administered 5 minutes before CCTA image acquisition. Typically, 400 to 800 µg of sublingual nitroglycerin is administered to achieve this effect.
• Ensure appropriate lead placement.
• Have the patient practice breath-holding prior to the test. 

Technique or Treatment

Contrast Administration

During diagnostic CCTA procedures, achieving an intra-arterial opacification of around 300 Hounsfield units is generally necessary. To accomplish this, most adults require 50 to 120 mL of iodinated contrast, injected at 5 to 7 mL/s. However, for larger patients or those undergoing coronary artery bypass graft evaluation, a higher injection rate of 6 to 7 mL/s may be used, given the larger vessels relative to native coronary arteries.

Biphasic injection protocols are used to prevent streak artifacts from high contrast concentrations in the right side of the heart. This involves injecting contrast followed by saline. If images of the right heart structures are also necessary, triphasic injection protocols can be implemented, which involve sequential injections of contrast, contrast-saline, and saline. The scanning time and infusion rate determine the total contrast volume required. Typically, 80 mL of contrast at 5 mL/s is administered for a coronary study using a biphasic injection protocol, followed by 40 mL of saline at the same rate.

Image Acquisition

The initial phase of image acquisition in CCTA includes scout images, typically acquired as low-energy scans at 120 kV and 35 mAs. Subsequently, the contrast transit time is determined to ensure maximal opacification of the coronary vessels during the scan. This is achieved through the 'test-bolus' method, in which contrast enhancement in the ascending aorta is timed at the carina level, thereby serving as a surrogate for the time required for contrast to reach the coronary arteries.

Subsequently, image acquisition parameters are meticulously configured. The 'half-scan' reconstruction algorithm, which combines simultaneous gantry rotation and scanner bed advancement to create a spiral trajectory (termed 'spiral' or 'helical' CT), is commonly employed. An optimal 'pitch,' defined as the ratio of bed movement to gantry rotation, is selected to avoid overlap or gaps in reconstruction. A balance is struck: greater overlap facilitates the omission of undesired image sets, thereby enabling subsequent reconstruction. However, lower pitches result in greater radiation exposure. Fast-pitch scanners reduce acquisition time and radiation exposure but are best suited for lower heart rates. The alternative mode, 'step and shoot,' maintains a static scanner bed while the gantry orbits the patient, generating a series of axial images.

With 320 detectors, a CT scanner performs cardiac imaging in a single rotation, an advancement over 64- or 128-detector systems. Two cardinal methods of cardiac image acquisition are retrospective and prospective. Retrospective acquisition involves imaging at 10% intervals throughout the cardiac cycle, using a tube modulator to reduce radiation dose during phases when high-quality reconstruction is unnecessary. The radiation exposure is maintained at 100% during phases critical for coronary artery evaluation. Tube modulation is more effective for reducing doses in patients with slower heart rates. Prospective reconstruction restricts radiation exposure to a predefined phase of the cardiac cycle, typically at 75% of the cycle duration, thereby substantially reducing radiation and making it a favored approach. Prospective electrocardiogram (ECG)-triggered acquisition aligns x-ray tube activation with mid-diastole, further minimizing exposure. Suboptimal heart rates permit end-systolic utilization. Irregular rhythms or high heart rates prompt retrospective ECG gating.

Several strategies are deployed to mitigate patient radiation exposure while preserving diagnostic accuracy. Delimiting the scan range confines radiation exposure solely to the structures under examination. Typically, the CCTA scan ranges from the inferior tracheal bifurcation to the lower cardiac border. Tube potential affects the x-ray beam energy; typical adult CCTA protocols use 100 kV to 120 kV. Higher potentials enhance tissue penetration but also increase radiation exposure. Tube current influences photon count per unit time; higher current reduces image noise but increases radiation dose. Anatomy-based tube current modulation adjusts the current during traversal of less-dense tissues, such as the lungs, thereby limiting exposure. ECG-based modulation reduces current during phases of pronounced cardiac motion, particularly early and midsystole, thereby reducing radiation exposure but potentially compromising diagnostic sensitivity in these motion-prone phases.

Postprocessing

The reconstruction of axial data is a critical step in assessing coronary arteries, cardiac function, and noncoronary structures. The rhythm must be analyzed and optimized to assess coronary health and prevent ectopic beats. The optimal phase of the cardiac cycle is then carefully selected, and the appropriate kernel and reconstruction parameters are determined. Both maximum intensity projection and multiplanar reformats are used to assess stenosis, with coronary stenosis reevaluated at a different cardiac phase to ensure accuracy.

For patients with irregular R-R intervals, such as those with atrial fibrillation, selecting a specific phase of the R-R interval can reconstruct different cardiac cycle phases and artifacts. To address this, the ECG is edited by selecting a phase based on a specified time window relative to the preceding R wave, such as 200 ms. The resulting artifact from beat-to-beat variability is known as a misalignment or banding artifact. The late-diastole phase (60%-80% of the R-R interval) is typically chosen for coronary evaluation. However, in some cases, a systolic phase (35% of the R-R interval) is selected to minimize motion artifacts, as motion is the least at this systolic stage.

Complications

CCTA testing centers should be equipped and staffed to manage the rare complication of anaphylaxis to any agent administered during testing. Standard oral steroids and pre-test diphenhydramine should be prescribed when specific contrast allergies are documented. CT scans use x-rays, an ionizing radiation that can damage cells on a molecular level. The potential for harm from radiation exposure is cumulative over a patient’s lifetime. Thus, children and young adults are particularly at risk. Organs with high cellular turnover are also at increased risk for genetic damage from ionizing radiation exposure. Radiation exposure during CCTA should be as low as reasonably achievable to obtain diagnostic results.

Clinical Significance

CCTA is a noninvasive, cost-effective, and accurate method for assessing CAD. This modality offers a timely method of anatomical evaluation of coronary arteries. CCTA provides a tremendous prognostic utility. The scope of CCTA in low-risk suspected acute coronary syndrome is also expanding. Additionally, it offers an alternative explanation for the symptoms by identifying noncoronary causes or congenital anomalies. Continued refinements in CT technology will help reduce patients' radiation exposure.

Enhancing Healthcare Team Outcomes

High-quality use of CCTA requires a coordinated, interprofessional strategy that aligns clinical judgment, technical expertise, and patient-centered decision-making. Clinicians must apply evidence-based risk stratification to identify appropriate candidates—particularly patients with stable or acute chest pain and intermediate pretest probability of coronary artery disease—while integrating CCTA results with clinical context to guide downstream management. Radiologists and cardiologists contribute specialized imaging interpretation skills, ensuring accurate assessment of coronary anatomy, plaque burden, and stenosis severity. Nurses play a critical role in patient preparation, including heart rate control, intravenous access, allergy screening, and patient education, which directly impacts image quality and safety. Pharmacists support safe medication use by advising on beta-blocker and nitrate administration, managing contrast-related risks, and reviewing potential drug interactions, particularly in patients with renal disease or complex medication regimens.

Effective interprofessional communication and care coordination are essential to optimize outcomes and minimize unnecessary testing or delays in care. Clear protocols and closed-loop communication among emergency medicine, cardiology, radiology, nursing, and pharmacy teams facilitate timely imaging, appropriate contrast use, and rapid reporting of results. Shared decision-making with patients—supported by consistent messaging from all team members—enhances understanding of the test's purpose, risks, and implications of the findings. Coordinated follow-up planning ensures that abnormal results prompt appropriate preventive therapy or referral, while normal studies safely reduce unnecessary admissions and invasive testing. Through collaborative workflows and defined roles, the healthcare team can leverage CCTA to improve diagnostic accuracy, patient safety, and overall team performance.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Neurauter E, Leschka S, Wildermuth S, Ehl NF, Joerg L, Rickli H, Maeder MT. Use of coronary computed tomography angiography in clinical practice - single centre experience in Switzerland in light of current recommendations based on pretest probability considerations. Swiss Med Wkly. 2019 Jan 14;149:w20010. [PubMed: 30685865]

2.

Bettencourt N. Management of patients after computed tomography coronary angiography: Evidence and room for improvement. Rev Port Cardiol (Engl Ed). 2019 Jan;38(1):51-52. [PubMed: 30685293]

3.

Bellinge JW, Majeed K, Carr SS, Jones J, Hong I, Francis RJ, Schultz CJ. Coronary artery 18F-NaF PET analysis with the use of an elastic motion correction software. J Nucl Cardiol. 2020 Jun;27(3):952-961. [PubMed: 30684262]

4.

Andreini D, Pontone G, Bartorelli AL, Agostoni P, Mushtaq S, Bertella E, Trabattoni D, Cattadori G, Cortinovis S, Annoni A, Castelli A, Ballerini G, Pepi M. Sixty-four-slice multidetector computed tomography: an accurate imaging modality for the evaluation of coronary arteries in dilated cardiomyopathy of unknown etiology. Circ Cardiovasc Imaging. 2009 May;2(3):199-205. [PubMed: 19808593]

5.

Andreini D, Pontone G, Mushtaq S, Conte E, Perchinunno M, Guglielmo M, Volpato V, Annoni A, Baggiano A, Formenti A, Mancini ME, Beltrama V, Ditali V, Campari A, Fiorentini C, Bartorelli AL, Pepi M. Atrial Fibrillation: Diagnostic Accuracy of Coronary CT Angiography Performed with a Whole-Heart 230-µm Spatial Resolution CT Scanner. Radiology. 2017 Sep;284(3):676-684. [PubMed: 28445682]

6.

Obisesan OH, Osei AD, Uddin SMI, Dzaye O, Blaha MJ. An Update on Coronary Artery Calcium Interpretation at Chest and Cardiac CT. Radiol Cardiothorac Imaging. 2021 Feb;3(1):e200484. [PMC free article: PMC7977732] [PubMed: 33778659]

7.

Gottlieb I, Bittencourt MS, Rochitte CE, Cavalcante JL. Coronary Computed Tomography Angiography Takes the Center Stage and Here is Why. Arq Bras Cardiol. 2019 Jan;112(1):104-106. [PMC free article: PMC6317632] [PubMed: 30673022]

8.

Qin L, Gu S, Chen C, Zhang H, Zhu Z, Chen X, Han Q, Yan F, Yang W. Initial exploration of coronary stent image subtraction using dual-layer spectral CT. Eur Radiol. 2019 Aug;29(8):4239-4248. [PubMed: 30666447]

9.

Sanz J. Imaging of Coronary Disease Hemodynamic Significance: And the Winner Is…. J Am Coll Cardiol. 2019 Jan 22;73(2):174-176. [PubMed: 30654889]

10.

Driessen RS, Danad I, Stuijfzand WJ, Raijmakers PG, Schumacher SP, van Diemen PA, Leipsic JA, Knuuti J, Underwood SR, van de Ven PM, van Rossum AC, Taylor CA, Knaapen P. Comparison of Coronary Computed Tomography Angiography, Fractional Flow Reserve, and Perfusion Imaging for Ischemia Diagnosis. J Am Coll Cardiol. 2019 Jan 22;73(2):161-173. [PubMed: 30654888]

11.

Narula J, Chandrashekhar Y, Ahmadi A, Abbara S, Berman DS, Blankstein R, Leipsic J, Newby D, Nicol ED, Nieman K, Shaw L, Villines TC, Williams M, Hecht HS. SCCT 2021 Expert Consensus Document on Coronary Computed Tomographic Angiography: A Report of the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr. 2021 May-Jun;15(3):192-217. [PMC free article: PMC8713482] [PubMed: 33303384]

Disclosure: Pirbhat Shams declares no relevant financial relationships with ineligible companies.

Disclosure: Omar Kousa declares no relevant financial relationships with ineligible companies.

Disclosure: Amgad Makaryus declares no relevant financial relationships with ineligible companies.